Principal Investigator
Alejandra Perez
Enrollment Status
Not Accepting
Clinical Trial ID
Institutional Protocol #
20230330
Clinical Trial Summary
A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients With ER+/HER2- Early Breast Cancer
Phase
Phase III
Funding Agency/Sponsor
Industrial
Disease
Breast Cancer
Contact Information
Phone Number
305-243-2647